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OBJECTIVE: Differentiating Parkinson’s disease (PD) from atypical parkinsonian disorders (APD) such as 
Multiple System Atrophy , parkinsonian type (MSA-p) or Progressive Supranuclear Palsy (PSP-RS) can be 
challenging. Early signs of postural Instability and gait disability (PIGD) are considered clues that may signal 
presence of APD. However, it remains unknown which PIGD test – or combination of tests – can best 
distinguish PD from APD.  We evaluated the discriminative value of several widely-used PIGD tests, and 
aimed to develop a short PIGD evaluation that can discriminate parkinsonian disorders.  
 
METHODS: In this multicentre cohort study patients were recruited by 11 European MSA Study sites. 
Patients were diagnosed using standardized criteria. Postural instability and gait disability was evaluated 
using interviews and several clinical tests.  
 
RESULTS: Nineteen PD, 21 MSA-p and 25 PSP-RS patients were recruited. PIGD was more common in APD 
compared to PD. There was no significant difference in axial symptoms between PSP-RS and MSA-p, except 
for self-reported falls (more frequent in PSP-RS patients). The test with the greatest discriminative power to 
distinguish APD from PD was the ability to perform tandem gait (AUC 0.83;95% CI 71-94; p<0.001), followed 
by the retropulsion test (AUC 0.8; 95% CI 0.69-0.91; p<0.001) and timed-up-and-go test (TUG) (AUC 
0.77;95% CI 0.64-0.9; p=0.001). The combination of these three tests yielded highest diagnostic accuracy 
(AUC 0.96;95% CI 0.92-1.0; p<0.001).  
 
CONCLUSIONS: Our study suggests that simple “bedside” PIGD tests – particularly the combination of 




















Differentiating Parkinson’s disease (PD) from atypical parkinsonian disorders (APD) such as the 
parkinsonian subtype of Multiple System Atrophy (MSA-p) or the classic Richardson’s Syndrome 
presentation of Progressive Supranuclear Palsy (PSP-RS) can be challenging due to overlap in clinical 
presentation. In early disease stages, patients with PSP-RS and MSA-p are therefore often misdiagnosed.[1, 
2] This is detrimental, because an accurate diagnosis is important for patient counselling, for instalment of 
treatment and to conduct proper research. There are clinical clues (often termed ‘red flags’) that can help 
differentiate between PD and APD. Some clues can occur in PSP-RS or MSA-p, but less commonly in PD.[3] 
The presence of postural instability or gait difficulties (PIGD) in early disease stages is such a clue, because 
these signs are seen regularly in early stages of APD, but only much later in the course of PD. Several simple 
tests can detect the presence of PIGD; examples include questions (can you still ride a bicycle?) or several 
gait and balance tests, such as the retropulsion test, single leg stance test, and timed-up-and-go (TUG) 
test.[4-8] However, it is unknown which gait and balance test, or which combination of tests, is most 
sensitive in discriminating between the early stages of PD and atypical parkinsonism (PSP-RS and MSA-p). It 
is also unknown whether these tests can discriminate between PSP-RS and MSA-p. To address these 
questions, we performed a multicentre study exploiting the European MSA Study Group network 
(www.emsa-sg.org), with the primary aim of evaluating the discriminative value of several gait and balance 
tests. Our secondary aim was to develop a short test battery for gait and balance evaluation that might be 
used as a simple bedside screening to discriminate PD from APD. 
 
Methods  
Participants and setting 
Between September 2011 and August 2013, consecutive outpatients were enrolled prospectively at 11 
EMSA centres. Limited follow-up was done in small subgroups, due to considerable numbers of dropouts. 
Here, we solely report on the cross-sectional data. Patients were diagnosed according to the UK Brain 
Bank[9], revised MSA consensus criteria[10] and NINDS-SPSP criteria.[11] Additional inclusion criteria were: 
age 30-90 years, ability to walk unassisted, and stable doses of dopaminergic replacement therapy for at 
least four weeks prior to examination. Exclusion criteria were: secondary cause of parkinsonism as detected 
by investigation(e.g. vascular parkinsonism, following accepted current criteria[12]), co-morbidities that 
substantially influenced the clinical presentation of PIGD, as judged by the local investigator (e.g. severe 
polyneuropathy); Hoehn and Yahr stage 4 or 5; prior brain surgery; presence of dementia or major 
depressive or psychotic disorder. In total 19 PD-patients, 21 MSA-p patients and 25 PSP-RS patients were 
enrolled. The study was performed in accordance with the declaration of Helsinki. Each study centre 
obtained local ethical approval. All participants gave their written informed consent prior to participation. 
 
General assessment of motor and cognitive functions  
A general assessment of motor and cognitive functions. In PD patients, disease severity was measured 
using the MDS-UPDRS.[13] The UMSARS was used in MSA-p patients[14] and PSP-Rating Scale was applied 
in PSP-RS patients.[15] Functional independence in daily living was rated with the Schwab & England scale; 
a score of 100% indicates a completely independent individual, and 0% indicates complete dependence. 
Cognitive assessment included the Frontal Assessment Battery (FAB), Mini Mental State Examination 
(MMSE) and Beck Depression Inventory (BDI).[16] 
 
Gait and balance assessment  
PIGD signs were evaluated using both history taking and physical examination. History taking included 
several questions that could be answered with yes or no. If patients were unable to answer the question, 
they were excluded for the corresponding analysis. We evaluated the following items:[8, 13, 17-21] 
- History of Freezing of Gait (FOG): participants were asked whether they had ever experienced FOG. 
FOG was explained as ‘feeling as if the feet were being glued to the floor, hampering effective 
forward stepping’. 
- Postural instability: we asked participants whether they were easily lost balance (with or without 















- Falling: we asked participants if they had fallen over the past 6 months. A fall was considered an 
event during which the individual had unintentionally come to rest on the ground or other lower 
level. 
- Difficulties arising from a chair: we asked participants whether they experienced difficulties arising 
from a chair, e.g. needing multiple attempts, being slow and clumsy, or unable to arise without 
using their arms. 
Bicycle sign: participants were asked if they could still ride a bicycle, or whether they had stopped 
riding a bicycle because of self-perceived balance impairment.  
Physical examination consisted of the following tests (see supplement 1 for details), performed in the 
following order: 
- Walking velocity, both under a single and dual tasking condition. 
- Timed-Up-and-Go-test (TUG): the time needed to stand up from a chair with arms, walk 3 meters at 
a comfortable pace, turn around, walk back to the chair and sit down.  
- FOG: rapid 360° turns, and walking fast with short steps. 
- Tandem gait (10 consecutive steps along a straight line at self-preferred speed, without support 
and with eyes open). This trial was performed  with and without an actual visually line  
- Single Leg Stance test (SLS): standing on one leg with hands held onto the hips, and with 
contralateral foot floating in the air, for as a long as possible or for a maximum duration of 30 
seconds.  
- Retropulsion test. 
 
All gait and balance items were videotaped and rated by a non-blinded experienced rater (CB). Participants 
were tested regardless of their medication dose cycle. Walking aids were not allowed. 
 
Statistical analysis 
ANOVA with alpha level 0.05 was used to determine which variables (age, disease duration, gender, 
Schwab & England score, MMSE, FAB, BDI, walking velocity, dual tasking, SLS, TUG and retropulsion test) 
and diagnosis (PD, MSA-p and PSP-RS) differed across groups. ANOVA was followed by post-hoc multiple 
comparison procedure Dunnett’s T3 test for the PIGD items, to identify differences between diagnosis 
groups whilst correcting for unequal variances. Pearson’s chi-square test or Fisher’s exact test were used to 
analyse nominal variables (levodopa benefit, tandem gait with/without cue, SLS <10 seconds, TUG >16 
seconds, history of FOG, falls in last 6 months, postural instability, difficulties arising from chair, bicycle 
sign, stopped walking when talking, and FOG), choosing Fisher’s exact test when criteria for Pearson’s chi-
square were not obtained. To evaluate the diagnostic effect size of PIGD tests, nonparametric receiver 
operating characteristics (ROC) curves were plotted and areas under curve (AUC) were calculated. Cut-off 
points were estimated using ROC curves for the TUG and SLS test. 
 
We first summarized PSP-RS and MSA-p patients under the umbrella term APD, and compared this group 
with PD, since this distinction is clinically most relevant. We then compared the MSA-p and PSP-RS groups. 
Finally, we included significant predictors found using the ROC’s in a multivariable binary logistic regression 
model, to test the discriminative value of these predictors together in differentiating APD from PD. Subjects 




PD, PSP-RS and MSA-p groups did not differ with respect to age, gender and disease duration (Table 1). 
Disease duration was calculated using year of symptom onset. PD subjects showed greater independence in 
daily living than patients with APD, as reflected by the Schwab & England scores (PD 88%; MSA-p 68%; PSP-
RS 66%; F2,58=17.5, p<.001). The proportion of subjects reporting levodopa benefit was significantly higher 
among PD patients. (. MMSE-scores were comparable across groups. PSP patients had more pronounced 
frontal executive dysfunction, as indicated by lower FAB scores (mean 11.96; standard deviation [SD] 4.08), 















Depression Inventory was lower in PD patients (mean 8.44; SD 5.82) compared to patients with MSA-p 
(12.86; SD 5.63) and PSP-RS (14.00; SD 8.67) (F2,58=3.5, p=.04). Post-hoc Dunnett t3 tests showed a 
significant difference between PSP-RS and MSA-p (p=.001). 
 
Postural instability and gait disability profiles 
Table 2 shows the results for PIGD items. Twenty-two percent of PD subjects reported postural instability, 
compared to 91% of PSP-RS patients, and 80% of MSA-p patients (χ²(2, N=60)= 23.42, p<.001). Difficulties 
arising from a chair were significantly less common in PD patients than in APD: 17% of PD patients reported 
difficulties in contrast to 77% of PSP-RS patients and 65% of MSA-p patients (χ²(2, N=60)= 1590, p<.001). 
Half of PD patients were still able to ride a bicycle, in contrast to 17% of PSP-RS patients (χ² (1, N =32) = 
4.07, p=0.044), and 6% of MSA-p patients (χ²(1, N=30)=7.31, p=.012). Almost all PSP-RS patients reported 
falls in the past 6 months (96%), whereas only 17% of the PD group reported a fall. Falls were also common 
in MSA-p patients, with 60% reporting falls (χ²(2, N =61)= 26.40, p<.001). PD subjects showed a faster mean 
walking velocity compared to PSP-RS patients and MSA-p patients, both with a dual task (F2,58=6.5, p=.003) 
and without (F2,55=7.1, p=.002). There was no group difference for the frequency of “stops with walking” 
during dual tasking. Patients with PD could stand longer on one leg during the SLS-test (17 sec; SD 10.8) 
compared to MSA-p patients (7.4 sec; SD 6.9) and PSP-RS patients (7.2 sec; SD 7.7) (F2,55=8.4, p=.001). 
Among PD patients, 60% could stand on one leg for 10 seconds, compared to only 25% of PSP-RS patients 
and 25% of MSA-p patients. Retropulsion test was normal in 83% of PD patients, compared to only 28% of 
PSP-RS patients and 44% of MSA-p patients (χ²(2, N=63)=15.45, p<.001). The same pattern was seen for 
tandem gait performance (no line ). Tandem gait was undisturbed (no single side-step) in 88% of PD 
patients, compared to only 15% of MSA-p patients and 30% of PSP-RS patients (χ²(2, N=60)=22.21, p< 
0.001). Comparable results were observed when tandem gait was performed with a line visually present 
(McNemar test, p=.344 (2 sided)). The time to complete the TUG-test was shorter in PD patients (12 sec; SD 
3.4) compared to PSP-RS patients (22 sec; SD 15.4) and MSA-p patients (18 sec; SD 6.5) (F2,57=5.4, p=.001). 
Most PD patients (98%) completed the TUG-test within 16 seconds, compared to only 26% of MSA-p 
patients and 40% of PSP-RS patients (χ²(2, N=61)= 14.90, p=.001). (Table 2) 
 
Diagnostic accuracy 
Figure 1 presents the AUC and 95% CI for the PIGD items when comparing PD vs APD. The history taking 
items that best discriminated between PD and APD were presence of subjective postural instability (AUC 
0.82; 95% CI 69-94; p<.001) and falls in the past 6 months (AUC 0.81; 95% CI 69-95; p<.001). The physical 
exam tests that best discriminated PD and APD were tandem gait performance (no line; AUC 0.83; 95% CI 
71-94; p<.001), followed by the TUG-test (AUC 0.83; 95% CI 72-94; p<.001). For clinical use, we estimated 
cut-off points for the TUG-test and the SLS-test, based on the optimal AUC curve. The most discriminative 
cut-off for the TUG-test was 16 seconds (AUC 0.77; 95% CI 64-90; p=.001) and 20 seconds for the SLS-test 
(AUC 0.71; 95% CI 55-86; p=.012). The retropulsion test yielded an AUC of 0.80 (95% CI 69-91). Logistic 
regression showed that discrimination rates were highest for the combination of TUG (cut-off 16 sec), 
tandem gait test (no line) and retropulsion test, with an AUC of 0.96 (95% CI 0.92-1.0; p<.001). Exchanging 




This study evaluated primarily which gait and balance tests might help to differentiate PD from two forms 
of APD (PSP-RS and MSA-p). We also investigated which tests might differentiate between MSA-p and PSP-
RS. Our results show that PIGD is more common in patients with MSA-p and PSP-RS than in patients with 
PD. The most sensitive single test to discriminate between PD and APD was the tandem gait test. Other 
discriminative tests included the TUG-test and retropulsion test. The combination of tandem gait test, TUG-
test (cut-off 16 sec) and retropulsion test yielded the highest diagnostic accuracy (AUC 0.96). Gait and 
















These results cannot be interpreted without considering possible group differences. The three groups did 
not differ with respect to gender, age and disease duration. Not surprisingly, the APD groups had greater 
disability, and PSP-RS patients had more pronounced frontal executive dysfunction compared to both MSA-
p and PD patients. Also, scores for mood were better for PD patients compared to both MSA-P patients 
and, particularly, PSP-RS patients. Importantly, all patients already fulfilled established clinical diagnostic 
criteria for PD, MSA-p and PSP-RS, so the test battery identified here essentially only confirmed what 
clinicians had already decided based upon the overall clinical presentation (which obviously also included 
some PIGD items). The present findings therefore need to be replicated in a cohort of patients in earlier 
disease stages (mean disease duration for the present cohort was 4 years, calculated since onset of first 
symptoms), when there is greater diagnostic uncertainty, to see if early detection of specific PIGD 
abnormalities can accelerate the differential diagnostic process. It would also be interesting to see if our 
test battery can reflect the degree of postural instability (it currently only evaluates the presence or 
absence of postural instability but does not yet accurately rate the severity). 
Clinicians currently use a variety of tests to evaluate the presence of PIGD-abnormalities, and this likely 
takes place very inconsistently across clinics, dictated by local customs, personal preferences, prior 
experience and perhaps time constraints. Here, we show that the combined performance of the tandem 
gait test, TUG-test and retropulsion test improves the sensitivity and at the same time avoids diagnostically 
superfluous, time-consuming, expensive and potentially harmful investigations. Obviously, the findings of 
our proposed test battery should never be judged in isolation during the diagnostic process. 
Implementation of the entire test battery as one part of an otherwise full exam might possibly lead to an 
accurate diagnosis in an earlier disease stages, which is of importance for patient counselling (patients are 
keen to know which disease they have, even when this does not have immediate treatment consequences)  
and inclusion in clinical trials (namely better exclusion of patients with atypical parkinsonism in trials that 
aim to include patients with PD, and vice versa). 
 
Tandem gait performance was the most sensitive test to separate PD from APD, with a sensitivity of 77% 
and specificity of 88% (AUC 0.83). This high discriminative value is in line with previous studies reporting a 
sensitivity ranging from 82-90.6%, a specificity ranging from 66-92% and AUC of 0.81.[7, 22, 23] The low 
specificity of 66.6% in one study[23] might have been related to the longer disease duration of participants 
in that study compared to the present one (8.4 vs 4 years). The new finding here is that the tandem gait 
test outperformed a wide range of other established PIGD questions and tests. Impaired tandem gait 
performance signals the presence of medio-lateral balance impairment, which is typically absent in early 
PD, but might develop later as the neurodegenerative process spreads.[18] In contrast, this more 
widespread neurodegeneration is already present in early stages of PSP-RS and MSA-p.[24, 25] Another 
new finding was the refinement of how tandem gait should be executed in clinical practice, to yield the best 
diagnostic value. Our results suggest that tandem gait performance can reveal medio-lateral balance 
impairment, independent of the presence of a visual reference on the floor. The TUG-test was the second-
best physical examination test to discriminate between PD and APD. Previous studies used the TUG-test 
mainly for a different purpose, namely to predict fall risks, and mainly in elderly populations.[26] In the PD 
patients tested here, a long TUG time (>16 sec) was also associated with an increased fall risk (OR 3.86, 95% 
CI 1.05,14.27, P=0.043), and this is in line with earlier work.[20]  Various studies have emphasized that 
patients with PD might be at risk of developing concurrent cerebrovascular lesions, and that such lesions 
may be clinically relevant.[27-29]Other patients may have vascular parkinsonism, i.e. parkinsonian signs 
that can be fully attributed to underlying cerebrovascular pathology.[12] It would be interesting to see if 
the TUG, retropulsion test and tandem gait performance also distinguish between PD and vascular 
parkinsonism, or whether development of concurrent cerebrovascular lesions in patients with otherwise 
typical PD might influence performance on the PIGD test battery. 
 
Our present findings also confirm the discriminative value of the ‘bicycle sign’ (having stopped riding a 
bicycle because of self-perceived instability), with an AUC (0.69 in the present study) that was largely 
comparable to a previous study (which reported an AUC of 0.74).[17] This is interesting, because the earlier 















study was performed not only in the Netherlands, but also in various different European countries, 
including those where cycling is not an integral part of the everyday lifestyle of patients. This suggests that 
the bicycle sign is  useful test even outside the Netherlands, as was also suggested by another study 
performed in Japan.[30] Note that the bicycle sign actually tests the same construct of medio-lateral 
instability as the tandem gait test. Tandem walking can serve as a simple  alternative for patients who have 
never cycled in their life. 
 
The combination of tandem gait test, TUG-test (cut-off 16s) and retropulsion test yielded the highest 
discriminative value. This specific combination is understandable because the three test are 
complementary, each exploring different constructs: tandem gait performance assesses medio-lateral 
instability; the TUG-test assesses transfers in and out of a chair with arms, walking and turning; and the 
retropulsion test assesses anterior-posterior instability. We suggest to use this combination as a short and 
simple bedside test battery to discriminate PD from APD. It is possible to exchange the retropulsion test for 
a history of subjective postural instability, as this combination also yielded a good accuracy (AUC 0.95). One 
advantage is that asking about subjective postural instability is less cumbersome than performing a 
retropulsion test. A disadvantage to asking about prior falls is over- or underreporting by the patient. We 
know that asking about prior falling is rather susceptible to recall bias. [31] History taking of postural 
instability and falling are not complementary, as both explore the same construct of anterior-posterior 
instability. Note that several commonly used tests did not contribute much to the differential diagnosis. 
This included the 360 degrees rapid turning test (to elicit FOG)[32, 33]), which was equally impaired in PD, 
MSA-p and PSP-RS. Standing on one leg was more frequently impaired among MSA-p and PSP-RS patients 
compared to PD patients, but added no further discriminatory value to the battery described above. Finally, 
the “stops walking while talking” – which is a good test to predict the risk of future falls – did not 
differentiate between the three groups. 
 
Our results show that presence or absence of PIGD cannot differentiate between MSA-p and PSP-RS. Both 
patient groups were comparable for all investigated items, except for presence of falls in the last 6 months, 
which was higher in PSP-RS patients compared to MSA-P patients. However, the mere presence of prior 
falls seems insufficient to reliably differentiate between MSA-p and PSP-RS.[31] For this purpose, careful 
evaluation of additional signs are needed, such as presence of supranuclear vertical gaze palsy or 
prominent early cognitive impairment (supporting a diagnosis of PSP-RS), and marked early autonomic 
dysfunction (supporting a diagnosis of MSA-p).[11, 34]  
 
Several limitations must be mentioned. Our study size was relatively small, hence the regression analysis 
might have generated an overestimate due to limited statistical power.  Additionally, the video-rater was 
not blinded, and future studies should preferably apply blinded video-rating.  Moreover a rate of 
misdiagnosis should be considered since we have no post-mortem examinations. As an acceptable 
surrogate for a definite neuropathological diagnosis, we used the clinical diagnosis by experts in movement 
disorders. Future studies remain needed to confirm the discriminative and longitudinal value of our bedside 
test battery, in particular in patients in very early disease stages who do not yet fulfil established criteria for 
a particular form of parkinsonism, and where the diagnostic uncertainty is greatest. Furthermore, all 
patients in the present study were tested while ON medication, the advantage being that this is how the 
large majority of patients will be tested in busy regular clinical practices. However, given the fact that the 
responsiveness to dopaminergic medication varied across the groups, this choice for testing in an ON state 
could have affected the results. We suspect that the influence of medication may not have been large, 
because many axial parkinsonian features tend to be largely resistant to dopaminergic medication. To 
examine this effect of medication on the discriminatory power, it would be interesting to test patients both 
OFF and ON medication. 
 
Our study focused primarily on separating the group of atypical parkinsonisms from PD, realizing that 
distinguishing between the various forms of atypical parkinsonism is much more difficult. This certainly 















stages. We acknowledge that our study is of limited value to make a differentiation between subgroups of 
parkinsonism, and we encourage that this issue will be addressed in future studies.  Finally, we 
acknowledge that there may be a difference in PIGD profile between PD subgroups (e.g. tremor 
predominant versus non-tremor predominant) and PSP subgroups (e.g. PSP-RS versus PSP-P), which we 
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(n=21) * P-value 
mean (range) mean (range) mean (range) 
Gender 15m 18m 11m n.s.  
Age at examination (years) 62 (41-81) 67 (57-79) 65    (50-80) n.s.  
Age at symptom onset (years) 56 (33-72) 63 (50-75) 61    (45-72) n.s.  
Disease duration (years) 4   (2-8) 4 (1-8) 4    (1-9) n.s.  
Levodopa benefit  100%(n=12ˣ) 33% (n=18) 63% (n=16) 0.004
a 
Schwab & England ADL scale 88% (80-100) 66% (40-90) 68% (50-100) <0.001
a,b 
Rating scales PD PSP-RS MSA-p 
UMSARS I 17 (8-35) 
UMSARS II 19 (12-37) 
MDS-UPDRS I 7  (2-16) 
MDS-UPDRS II 9   (0-17) 
MDS-UPDRS III 24  (9-34) 
PSPRS 36 (15-60) 
Cognitive function assessment PD PSP-RS MSA-p 
MMSE   28 (21-30) 27 (23-30) 28 (14-30) n.s.  
FAB 16 (9-18) 12 (3-18) 16 (9-18) <0.001
a,c
 
BDI 8 (0-23) 14 (0-37) 13 (2-22) 0.039 
 
M: men, Age at examination and age at symptom onset are in years. Activities of daily living scale according to the modified 
Schwab and England scale (score 0-100%), UMSARS Unified Multiple system Atrophy Rating Scale part I (score 0-48), UMSARS 
part II (score 0-56), UPDRS MDS unified Parkinson’s disease rating scale part I  (0-52), UPDRS  part II (score 0-52), UPDRS part III 
(score 0-132), PSPRS Progressive Supranuclear Palsy Rating Scale (score 0-100), FAB Frontal Assessment Battery (score 0-18), 
MMSE Mini Mental State Examination (0-30), BDI Becks depression inventory (0-63) score (0-13), light (14-19), moderate (20-28), 
(severe 29-63) M=male 
For MDS-UPDRS, UMSARS and PSPRS higher scores indicate worse functioning. For activities of daily living scale, FAB and MMSE 
lower scores indicate worse functioning. N.S. not statistically significant. 
 
ˣ 7 PD patients had never used levodopa, they were therefore scored as unknown and were excluded from this table. 
 
*P-value for the comparison of PD, MSA-P and PSP-RS by analysis of variance (ANOVA) for continuous variables or Pearson’s chi 




 indicates significant difference between PSP and PD p<0.05, 
b
 indicates significant difference between MSA and PD p<0.05, 
c














Table 2 Postural instability and gait disorder items 
PD PSP-RS MSA-p 
History mean ± SD n= mean ± SD n= mean ± SD n= p-value 
History of FOG 17% 18 39% 23 45% 20  0.155  
Postural Instability 22% 18 91% 22 80% 20  <0.001  
Falls in last 6 months 17% 18 96% 23 60% 20  <0.001  
Difficulties arising from chair 17% 18 77% 22 65% 20  <0.001  
Bicycle sign (stopped riding) 50% 14 83% 18 94% 16  0.019  
Physical examination 
Comfortable walking velocity (m/s) 0.8 ± 0.2 18 0.5± 0.3 24 0.6± 0.2 20  0.002  
Comfortable walking velocity dual tasking (m/s) 0.6 ± 0.2 18 0.4 ± 0.2 23 0.5± 0.2 20  0.003  
Difference walking velocity single and dual tasking 0.17 ± 0.2 18 0.15 ± 0.1 23 0.14 ± 0.1 20  0.870  
Difference between single and dual tasking steps 0.17 ± 0.2 18 1.8 ± 4.1 20 2.1 ± 4.2 17 
Stopped walking when talking 16% 19 40% 25 35% 20  0.208  
Single leg stance test (s) 16.6 ± 10.8 18 7.4± 6.9 24 7.2±7.7 20  0.001  
Single leg stance test < 10s *  39% 18 75% 24 75% 20  0.026 
Single leg stance test <20 s 50% 18 96% 24 85% 20  0.001 
retropulsion test (score according MDS-UPDRS)  0.2 ± 0.5 18 1.8 ±1.5 25 1.7±1.5 20  0.001  
0: normal no problems, 1-2 steps 83% 28% 44% 
1: slight 3-5 steps 11% 26% 22% 
2: mild >5 steps, unaided recovery 6% 0% 2% 
3: moderate: falls if not caught 0% 28% 22% 
4: severe: very unstable 0% 16% 10% 
Timed up and go (s) 12 ±3.4 22.4± 15.4 24 18.0± 6.5 20  0.007  
Timed up and go > 16s* 12% 17 71% 24 60% 20 < 0.001  
Freezing of Gait 22% 18 32% 25 40% 20  0.501  
Tandem gait (NO line present): without side steps    88% 17 30% 23 15% 20  <0.001  
Tandem gait (line visually present): without side steps  77% 17 22% 23 15% 20  <0.001  
 
*cut off points as described by
5, 8
. FOG freezing of gait 
P-value for the comparison of PD, MSA-p and PSP-rs by analysis of variance (ANOVA) for continuous variables or Pearson’s 
chi square tests for the categorical variable. After significant group interactions, post hoc Dunnett’s t3 and paired chi square 
tests were performed. All items were significant (p<0.05) for PD vs MSA or PSP, only falls indicates significant difference 




























Diagnostic effect size between PD and atypical parkinsonism for each PIGD test obtained by area under the curve (AUC). 
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• Postural instability is more common in atypical parkinsonism than Parkinson’s disease 
 
• Tandem gait performance discriminates between atypical parkinsonism and PD 
 
• Impaired tandem gait performance indicates medio-lateral balance impairment 
 
• Combined tests can improve sensitivity and speed up clinical examination 
 
 
 
